Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
9.300
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 11, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
↗
Today 6:13 EST
Compass Pathways (NASDAQ:CMPS) has completed its application for U.S. approval of COMP360, its proprietary synthetic psilocybin formulation for treatment-resistant depression, and is preparing for a...
Via
MarketBeat
Topics
Cannabis
Government
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
November 11, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
November 09, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 05, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways (NASDAQ:CMPS) Narrows Q3 Loss as Final NDA Submission Nears
↗
November 03, 2026
Via
Chartmill
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
November 04, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways: 3 Key Takeaways for Long-Term Investors
↗
November 03, 2026
Its clinic network of more than 8,500 interventional psychiatry centers gives COMP360 a ready path to patients once approved.
Via
The Motley Fool
Topics
Earnings
Compass Pathways (CMPS) Q3 2026 Earnings Call Transcript
↗
November 03, 2026
COMP360 targets first-half 2027 launch with $444M cash backing regulatory approval.
Via
The Motley Fool
Topics
Earnings
Compass Pathways Q3 Earnings Call Highlights
↗
November 03, 2026
Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within...
Via
MarketBeat
Topics
Cannabis
Earnings
Government
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
November 03, 2026
From
Compass Pathfinder Limited
Via
Business Wire
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
November 02, 2026
From
Compass Pathfinder Limited
Via
Business Wire
1 Reason Compass Pathways Is Worth a Second Look This Month
↗
November 02, 2026
An accelerated FDA review could benefit Compass Pathways.
Via
The Motley Fool
Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
October 28, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
October 27, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day
October 14, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Appoints Kelley Boucher as Chief People Officer
September 30, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch
↗
September 24, 2026
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial...
Via
MarketBeat
Topics
Cannabis
Government
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data
↗
September 22, 2026
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its...
Via
MarketBeat
Topics
Cannabis
Government
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances
↗
September 22, 2026
Compass Pathways (NASDAQ:CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter,...
Via
MarketBeat
Topics
Cannabis
Government
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears
↗
September 22, 2026
Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a...
Via
MarketBeat
Topics
Cannabis
Government
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026
September 16, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
September 15, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training
September 10, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways to Participate in Investor Conferences the Week of September 14th
September 10, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways’ New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year
September 09, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026
September 08, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 03, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree
September 02, 2026
From
Compass Pathfinder Limited
Via
Business Wire
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026
September 01, 2026
From
Compass Pathfinder Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
